Lincoln Pharmaceuticals (531633) Q2 2026 earnings summary

Executive summary

• Consolidated net profit for Q2 FY26 was Rs. 20.01 crore, down 24.06% year-over-year; total income for the quarter was Rs. 170.60 crore, a slight decrease of 0.34% year-over-year.

• For the half year ended September 2025, consolidated net profit was Rs. 47.71 crore, down 4.64% year-over-year, with total income rising 3.36% to Rs. 339.93 crore.

• The company targets Rs. 1,000 crore revenue in three years, aiming for 15-18% annual growth, focusing on cardiac, diabetic, dermatology, and ENT segments.

• Dividend of Rs. 1.80 per share for FY24-25 approved at the 31st AGM.

• FIIs increased their holding to 4.73% as of September 30, 2025.

Financial highlights

• Q2 FY26 EBITDA was Rs. 32.66 crore, down 14.86% year-over-year; H1 FY26 EBITDA was Rs. 71.74 crore, up 0.34% year-over-year.

• Q2 FY26 EPS was Rs. 9.98, down 24.11% year-over-year; H1 FY26 EPS was Rs. 23.79, down 4.69% year-over-year.

• Standalone net profit for H1 FY26 was Rs. 47.71 crore, down 4.64% year-over-year; total income for H1 FY26 was Rs. 339.93 crore, up 3.36%.

• As of September 30, 2025, consolidated total assets stood at Rs. 85,450.90 lakh, with equity of Rs. 71,576.82 lakh.

• Cash and cash equivalents increased to Rs. 2,027.90 lakh at the end of H1 FY26.

Outlook and guidance

• Management reiterates a strategic goal of Rs. 1,000 crore revenue within three years, supported by expansion into high-value therapeutic segments and new markets.

• Company expects to maintain 15-18% annual growth, leveraging R&D, operational excellence, and a strong product pipeline.

• Plans to expand exports from 60+ to 90 countries in the next 2-3 years, with recent entry into Canada and regulatory approvals from TGA-Australia and EU GMP.